ʻAka Tranexamic

Inoa Huahana: Tranexamic Acid 98% na HPLC
Helu CAS:1197-18-8
Huina Molekala: C₈H₁₅NO₂
Kaumaha Molekala: 157.21 g/mol
Maʻemaʻe: ≥98% (HPLC)
Nānā: ʻO ka pauka kristal keʻokeʻo
Waihona: +4°C (manawa pōkole), -20°C (lōʻihi)
Hoʻohana: Lapaʻau, Kosmetics, Research

1. Nānā Huahana

Hoʻohana nui ʻia ʻo Tranexamic Acid (TXA), kahi analog lysine synthetic, ma ke ʻano he antifibrinolytic agent e hōʻemi i ke koko i ka hoʻonohonoho ʻana a me ka trauma. Hana ʻia kēia huahana ma lalo o ka mana koʻikoʻi o ka maikaʻi, e hōʻoia ana i ka maʻemaʻe o ≥98% e like me ka hōʻoia ʻia e High-Performance Liquid Chromatography (HPLC). ʻO kona ʻano kemika (trans-4-(aminomethyl)cyclohexanecarboxylic acid) a me ke kūpaʻa kiʻekiʻe e kūpono ia no nā noi like ʻole, me:

• Hoʻohana Lapaʻau: Ka mālama ʻana i ka hemorrhage, ka mālama ʻana i ka ʻeha lolo traumatic (TBI).
• Mea hoʻomaʻemaʻe: Nā ʻili keʻokeʻo ʻili e kuhikuhi ana i ka hyperpigmentation.
• Noiʻi: Hoʻomohala ʻana i ke ʻano loiloi a me nā haʻawina pharmacokinetic.

2. Kemimi a me ke Kino

• IUPAC Inoa: 4-(Aminomethyl)cyclohexane-1-carboxylic acid
• NUI: NC[C@@H]1CCC@HC(=O)O
• Ki InChI: InChI=1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)/t6-,7
• Lae hehee: 386°C (dec.)
• Solubility: Hiki ke hoʻoheheʻe ʻia i ka wai (1N HCl, pH-adjusted buffers), methanol, a me ka acetonitrile.

3. Hōʻoia maikaʻi

3.1 Nānā HPLC

ʻO kā mākou hana HPLC e hōʻoia i ka helu pololei a me ka hoʻopili ʻana i ka haumia:

• Kona: XBridge C18 (4.6 mm × 250 mm, 5 μm) a i ʻole like.
• Māhele Mobile: Methanol: acetate buffer (20 mM, pH 4) (75:25 v/v).
• Kahe Kahe: 0.8–0.9 mL/min.
• ʻIke: UV ma 220 nm a i ʻole 570 nm (ma hope o ka derivatization me 1% ninhydrin).
• Pono Pūnaehana:
  • Ka pololei: ≤2% CV no ka wahi kiʻekiʻe (6 replika).
  • Hoʻihoʻi hou: 98–102% (80%, 100%, 120% kiʻekiʻe spiked).

3.2 Palapala Hoʻomaʻemaʻe

• Ka haumia A: ≤0.1%.
• haumia B: ≤0.2%.
• Huina paumaele: ≤0.2%.
• Halides (e like me Cl⁻): ≤140 ppm.

3.3 Paʻa

• Ka Paʻa pH: He kūpono me nā mea pale (pH 2–7.4) a me nā hoʻonā IV maʻamau (e laʻa, fructose, sodium chloride).
• Paʻa wela: Paʻa ma 37°C no 24 mau hola i nā matrices biological.

4. Nā noi

4.1 Hoʻohana Lapaʻau

• Hoʻomaʻamaʻa Trauma: Hoʻemi i ka make ma nā maʻi TBI e 20% (CRASH-3 ho'āʻo).
• ʻO ke ʻoki ʻana: Hoʻemi i ke kahe o ke koko perioperative (orthopedic, ʻoki puʻuwai).

4.2 Mea hoʻonani

• Mechanism: Kāohi i ka plasmin-induced melanogenesis ma ke kāohi ʻana i nā pūnaewele lysine-binding.
• Nā ʻano hana: 3% TXA creams no ka melasma a me ka hyperpigmentation.
• Palekana: ʻAʻole ka hoʻohana ʻana i ke kumuhana i nā pilikia ʻōnaehana (e laʻa, thrombosis).

4.3 Noiʻi & Hoʻomohala

• Analytical Methods: Synthesis: Prodrug interconversion study under acidic conditions.
  • UPLC-MS/MS: No ka nānā 'ana i ka plasma (LOD: 0.1 ppm).
  • Fluorimetry: Derivatization me NDA/CN (5 mau minuke pane).

5. Packaging & Storage

• Hoʻopili mua: Hoʻopaʻa ʻia nā ʻeke alumini me ka desiccant.
• Noho ʻia: 24 mahina ma -20°C.
• Hoʻouna: Ambient wela (hōʻoia no 72 hola).

6. Palekana a me ka Hoʻokō

• Hoʻohana: E hoʻohana i ka PPE (mau mīkina lima, nā maka aniani) e pale aku i ka inhalation/contact.
• Kūlana Hoʻoponopono: Hoʻokō me USP, EP, a me JP pharmacopeias.
• ʻona: LD₅₀ (waha, ʻiole)> 5,000 mg / kg; non-carcinogenic.

7. Hoike

1. Hōʻoia kūpono ʻōnaehana no HPLC.
2. ʻO ke kāʻei calibration a me nā protocol derivatization.
3. UPLC-MS/MS hoʻohālikelike ʻano hana.
4. ʻO ke kumu kūʻai i ka mālama trauma.
5. ʻO ke kūpaʻa o ka hoʻokumu ʻana i nā mea hoʻonaninani.

Hua'ōlelo: Tranexamic Acid 98% HPLC, Antifibrinolytic Agent, Skin Whitening, Trauma Care, UPLC-MS / MS, CRASH-3 Trial, Melasma Treatment

ʻO ka wehewehe ʻana Meta: ʻAka Tranexamic Acid maʻemaʻe kiʻekiʻe (≥98% e HPLC) no ka hoʻohana ʻana i ka lāʻau lapaʻau, hoʻonaninani, a me ka noiʻi. ʻO nā ʻano hana HPLC i hōʻoia ʻia, ka mālama ʻana i ka trauma koʻikoʻi, a me nā ʻano kumuhana palekana. CAS 1197-18-8.